Efficacy and safety of omalizumab (anti-IgE monoclinal antibody) on oral immunotherapy for patients with cow's milk allergy (randomized control study)
Not Applicable
- Conditions
- food allergy
- Registration Number
- JPRN-UMIN000015545
- Lead Sponsor
- The Mami Mizutani foundation Kansai Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)severe bronchial asthma 2)severe atopic dermatitis 3)acute severe illenes 4)Decision of ineligibility by a physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of the symptom provocation threshold change at the time of entry and 8 months after the start of administration of Omalizumab.
- Secondary Outcome Measures
Name Time Method